Internal Medicine, Hematology & Oncology · Gilbert, AZ
NPI
1790980316
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2940 E Banner Gateway Dr, #450
Gilbert, AZ, 85234
Phone (480) 256-6444
Groups this clinician bills Medicare through
Medicare paid, 2024
$35K
420 services
Medicare patients, 2024
143
Average age 73
Drug cost, 2024
$5.1M
1,386 prescriptions
Company payments, 2025
$516
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew L Ulrickson was code 99233 (hospital e&m - subsequent), 158 times for 36 patients. In total Matthew L Ulrickson billed 420 services in 12 codes, and Medicare paid $35K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 158 | 36 | $90.99 | $14K |
| 99214 Office E&M - Established | Facility | 77 | 50 | $71.83 | $5,531 |
| 99215 Office E&M - Established | Facility | 70 | 49 | $111.06 | $7,774 |
| 99232 Hospital E&M - Subsequent | Facility | 51 | 18 | $58.36 | $2,976 |
| 99213 Office E&M - Established | Facility | 22 | 22 | $41.49 | $913 |
| 99205 Office E&M - New | Facility | 11 | 11 | $138.23 | $1,521 |
By year: 2022 $31K for 384 services; 2023 $43K for 539 services; 2024 $35K for 420 services.
Medicare prescription drug claims, 2024
In 2024, the drug Matthew L Ulrickson prescribed most often to Medicare patients was Valacyclovir (Valacyclovir Hcl), with 173 prescriptions and refills. In total Matthew L Ulrickson wrote 1,386 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Valacyclovir Valacyclovir Hcl | 173 | 415 | 67 | $12K |
| Pantoprazole Sodium Generic | 84 | 142 | 30 | $623 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 82 | 106 | 23 | $484 |
| Jakafi Ruxolitinib Phosphate | 73 | 73 | Under 11 | $1.1M |
| Fluconazole Generic | 60 | 104 | 20 | $4,948 |
| Venclexta Venetoclax | 51 | 51 | Under 11 | $247K |
| Potassium Chloride Generic | 38 | 55 | 19 | $477 |
| Posaconazole Generic | 33 | 33 | 14 | $49K |
| Vancomycin Hcl Generic | 32 | 32 | Under 11 | $5,393 |
| Idhifa Enasidenib Mesylate | 32 | 32 | Under 11 | $1.1M |
| Tibsovo Ivosidenib | 31 | 31 | Under 11 | $731K |
| Rosuvastatin Calcium Generic | 31 | 71 | 12 | $255 |
| Eliquis Apixaban | 28 | 36 | Under 11 | $21K |
| Ondansetron Hcl Generic | 27 | 29 | 21 | $959 |
| Tamsulosin Hcl Generic | 24 | 38 | Under 11 | $351 |
Brand drugs: - claims; generic drugs: 1,013 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew L Ulrickson $516 ($516 in general payments such as food, travel and fees) from 5 companies. The largest payer was Celgene Corporation with $218.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.